Cluster Headache
Conditions
Brief summary
Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.
Interventions
DRUGVerapamil
Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache. The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
prospective cohort, interventional , multicentric study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient 18 years old, and older * patient suffering from Cluster Headache (according to the l'ICHD-3 diagnostic criterias) * patients affiliated to the social security * patient that has given his full written consent to participate in the study * female patients participating in the study must be using an efficient contraception for more than 1 month prior to the beginning of the study
Exclusion criteria
* patient presenting contraindications to the use of verapamil * patient observing a treatment with ivabradine (Procoralan®), bétablockers, colchicine, l'esmolol, triazolam, quinidine. * patient under justicial protection * patient breastfeeding, or pregnant * patient suffering from a neuromuscular transmisson disease * patient with a pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the atrioventricular block when verapamil is used in prevention of Cluster Headache. | 27 months | Occurrence of the ratio of patients presenting a first degree atrioventricular block |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of the different atrioventricular conduction abnormities and their incidence | 27 months | Study of ECG results |
| Evaluation of the plasmatic concentration of verapamil and its metabolite (nor verapamil) in parallel with the occurrence of conduction abnormalities detected by electrocardiogram | 27 months | Plasmatic concentration of verapamil and its metabolite (nor verapamil) dosed at each visit |
| Relation between pharmacokinetic/ pharmacodynamics of verapamil and the appearance of conduction abnormalities to determinate the maximal tolerated dose of verapamil. | 27 months | The maximal tolerated dose of verapamil will be determined thanks to correlation between ECG results and Pharmacocinetics and pharmacodynamics |
Countries
France
Outcome results
None listed